1
|
Mundhe D, Mishra R, Basu S, Dalal S, Kumar S, Teni T. ΔNp63 overexpression promotes oral cancer cell migration through hyperactivated Activin A signaling. Exp Cell Res 2023; 431:113739. [PMID: 37567436 DOI: 10.1016/j.yexcr.2023.113739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Revised: 07/19/2023] [Accepted: 08/04/2023] [Indexed: 08/13/2023]
Abstract
Oral cancer is a common malignant tumor of the oral cavity that affects many countries with a prevalent distribution in the Indian subcontinent, with poor prognosis rate on account of locoregional metastases. Gain-of-function mutations in p53 and overexpression of its related transcription factor, p63 are both widely reported events in oral cancers. However, targeting these alterations remains a far-achieved aim due to lack of knowledge on their downstream signaling pathways. In the present study, we characterize the isoforms of p63 and using knockdown strategy, decipher the functions and oncogenic signaling of p63 in oral cancers. Using Microarray and Chromatin Immunoprecipitation experiments, we decipher a novel transcriptional regulatory axis between p63 and Activin A and establish its functional significance in migration of oral cancer cells. Using an orally bioavailable inhibitor of the Activin A pathway to attenuate oral cancer cell migration and invasion, we further demonstrate the targetability of this signaling axis. Our study highlights the oncogenic role of ΔNp63 - Activin A - SMAD2/3 signaling and provides a basis for targeting this oncogenic pathway in oral cancers.
Collapse
Affiliation(s)
- Dhanashree Mundhe
- Teni Laboratory, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Plot No. 1 & 2, Sector 22, Kharghar, Navi Mumbai, 410210, Maharashtra, India; Homi Bhabha National Institute, 2nd Floor, Training School Complex, Anushaktinagar, Mumbai, 400094, Maharashtra, India
| | - Rupa Mishra
- Teni Laboratory, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Plot No. 1 & 2, Sector 22, Kharghar, Navi Mumbai, 410210, Maharashtra, India; Homi Bhabha National Institute, 2nd Floor, Training School Complex, Anushaktinagar, Mumbai, 400094, Maharashtra, India
| | - Srikanta Basu
- Cell and Tumor Biology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Plot No. 1 & 2, Sector 22, Kharghar, Navi Mumbai, 410210, Maharashtra, India; Homi Bhabha National Institute, 2nd Floor, Training School Complex, Anushaktinagar, Mumbai, 400094, Maharashtra, India
| | - Sorab Dalal
- Cell and Tumor Biology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Plot No. 1 & 2, Sector 22, Kharghar, Navi Mumbai, 410210, Maharashtra, India; Homi Bhabha National Institute, 2nd Floor, Training School Complex, Anushaktinagar, Mumbai, 400094, Maharashtra, India
| | - Sanjeev Kumar
- BioCOS Life Sciences Private Limited, AECS Layout, B-Block, Singasandra, Hosur Road, 851/A, Bengaluru, 560068, Karnataka, India; Department of AIML- Computer Science, School of Engineering, Dayananda Sagar University, Bengaluru, 560068, Karnataka, India
| | - Tanuja Teni
- Teni Laboratory, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Plot No. 1 & 2, Sector 22, Kharghar, Navi Mumbai, 410210, Maharashtra, India; Cell and Tumor Biology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Plot No. 1 & 2, Sector 22, Kharghar, Navi Mumbai, 410210, Maharashtra, India.
| |
Collapse
|
2
|
Sharma D, Pawar SN, Sulkshane P, Waghole R, Yasser M, Pawar SS, Kannan S, Chaudhary N, Kalwar A, Patil R, Nair S, Dalal SN, Teni T. Elevated translationally controlled tumour protein promotes oral cancer progression and poor outcome. J Oral Pathol Med 2023; 52:849-859. [PMID: 37573872 DOI: 10.1111/jop.13467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 06/28/2023] [Accepted: 07/05/2023] [Indexed: 08/15/2023]
Abstract
BACKGROUND Translationally controlled tumour protein (TCTP) is a multifunctional protein elevated in multiple cancers. However, studies on its role in oral carcinogenesis and prognosis are rare. We recently reported the role of its interacting partner, MCL1, in oral cancer progression and outcome. Hence, the present study aimed to assess TCTP expression in oral tumorigenesis and its association with patient outcomes alone and in combination with MCL1. METHODS TCTP expression was assessed by immunohistochemistry and immunoblotting in oral tissues and cells, respectively. Cell viability post siRNA/dihydroartemisinin treatment was analysed by tetrazolium salt assay. Cell survival, invasion and tumorigenic potential post TCTP knockdown were assessed by clonogenic, Matrigel and soft-agar assays, respectively. The association of TCTP with patient outcome was analysed by Kaplan-Meier and Cox regression. RESULTS TCTP was significantly overexpressed in oral premalignant lesions (p < 0.0001), oral tumours (p < 0.0001) and oral dysplastic and cancer cells versus normal oral mucosa and also in recurrent (p < 0.05) versus non-recurrent oral tumours. Further, elevated TCTP was significantly (p < 0.05) associated with poor recurrence free survival (RFS) and poor overall survival (OS; hazard ratio = 2.29; p < 0.05). Intriguingly, the high co-expression of TCTP and MCL1 further reduced the RFS (p < 0.05) and OS (p < 0.05; hazard-ratio = 3.49; p < 0.05). Additionally, TCTP knockdown decreased survival (p < 0.05), invasion (p < 0.01) and in vitro tumorigenic potential (p < 0.0001). Dihydroartemisinin treatment reduced TCTP levels and viability of oral cancer cells. CONCLUSION Our studies demonstrate an oncogenic role of TCTP in oral cancer progression and poor outcome. Thus, TCTP may be a potential prognostic marker and therapeutic target in oral cancers.
Collapse
Affiliation(s)
- Dipti Sharma
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
- Homi Bhabha National Institute (HBNI), Mumbai, India
| | - Sagar N Pawar
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
| | - Prasad Sulkshane
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
| | - Rohit Waghole
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
| | - Mohd Yasser
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
| | - Sushil S Pawar
- Department of Oral Pathology & Microbiology, KBH Dental College and Hospital, Nashik, India
| | - Sadhana Kannan
- Clinical Research Secretariat, ACTREC, TMC, Navi Mumbai, India
| | - Nazia Chaudhary
- Homi Bhabha National Institute (HBNI), Mumbai, India
- Cell and Tumor Biology, ACTREC, TMC, Navi Mumbai, India
| | - Anjali Kalwar
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
| | - Rahul Patil
- Department of Oral Pathology & Microbiology, KBH Dental College and Hospital, Nashik, India
| | - Sudhir Nair
- Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
| | - Sorab N Dalal
- Homi Bhabha National Institute (HBNI), Mumbai, India
- Cell and Tumor Biology, ACTREC, TMC, Navi Mumbai, India
| | - Tanuja Teni
- Teni Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Navi Mumbai, India
- Homi Bhabha National Institute (HBNI), Mumbai, India
| |
Collapse
|
3
|
You JR, Chen YT, Hsieh CY, Chen SY, Lin TY, Shih JS, Chen GT, Feng SW, Peng TY, Wu CY, Lee IT. Exploring Possible Diagnostic Precancerous Biomarkers for Oral Submucous Fibrosis: A Narrative Review. Cancers (Basel) 2023; 15:4812. [PMID: 37835505 PMCID: PMC10571555 DOI: 10.3390/cancers15194812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 09/27/2023] [Accepted: 09/28/2023] [Indexed: 10/15/2023] Open
Abstract
Oral submucous fibrosis (OSF) stands as a progressive oral ailment, designated as a potentially malignant disorder. OSF has gained widespread recognition as a significant precursor to malignant transformation. In the pursuit of dependable, straightforward, and non-invasive diagnostic measures for the early detection of oral malignant progression, research has delved into potential diagnostic biomarkers of OSF. This comprehensive review delves into current investigations that explore the correlation between various biomarkers and OSF. The molecular biomarkers of OSF are categorized based on cytology and sampling methods. Moreover, this review encompasses pertinent studies detailing how these biomarkers are acquired and processed. Within this scope, we scrutinize four potential biomarkers that hold the promise of facilitating the development of diagnostic tools for detecting early-stage OSF.
Collapse
Affiliation(s)
- Jie-Ru You
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; (J.-R.Y.); (Y.-T.C.); (C.-Y.H.); (S.-Y.C.); (T.-Y.L.); (J.-S.S.); (G.-T.C.); (S.-W.F.); (T.-Y.P.)
| | - Ya-Ting Chen
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; (J.-R.Y.); (Y.-T.C.); (C.-Y.H.); (S.-Y.C.); (T.-Y.L.); (J.-S.S.); (G.-T.C.); (S.-W.F.); (T.-Y.P.)
| | - Chia-Yu Hsieh
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; (J.-R.Y.); (Y.-T.C.); (C.-Y.H.); (S.-Y.C.); (T.-Y.L.); (J.-S.S.); (G.-T.C.); (S.-W.F.); (T.-Y.P.)
| | - Sin-Yu Chen
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; (J.-R.Y.); (Y.-T.C.); (C.-Y.H.); (S.-Y.C.); (T.-Y.L.); (J.-S.S.); (G.-T.C.); (S.-W.F.); (T.-Y.P.)
| | - Tzu-Yao Lin
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; (J.-R.Y.); (Y.-T.C.); (C.-Y.H.); (S.-Y.C.); (T.-Y.L.); (J.-S.S.); (G.-T.C.); (S.-W.F.); (T.-Y.P.)
| | - Jing-Syuan Shih
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; (J.-R.Y.); (Y.-T.C.); (C.-Y.H.); (S.-Y.C.); (T.-Y.L.); (J.-S.S.); (G.-T.C.); (S.-W.F.); (T.-Y.P.)
| | - Guan-Ting Chen
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; (J.-R.Y.); (Y.-T.C.); (C.-Y.H.); (S.-Y.C.); (T.-Y.L.); (J.-S.S.); (G.-T.C.); (S.-W.F.); (T.-Y.P.)
| | - Sheng-Wei Feng
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; (J.-R.Y.); (Y.-T.C.); (C.-Y.H.); (S.-Y.C.); (T.-Y.L.); (J.-S.S.); (G.-T.C.); (S.-W.F.); (T.-Y.P.)
| | - Tzu-Yu Peng
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; (J.-R.Y.); (Y.-T.C.); (C.-Y.H.); (S.-Y.C.); (T.-Y.L.); (J.-S.S.); (G.-T.C.); (S.-W.F.); (T.-Y.P.)
| | - Chia-Yu Wu
- Division of Oral and Maxillofacial Surgery, Department of Dentistry, Taipei Medical University Hospital, Taipei 11031, Taiwan
- School of Dental Technology, College of Oral Medicine, Taipei Medical University, Taipei 11031, Taiwan
| | - I-Ta Lee
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; (J.-R.Y.); (Y.-T.C.); (C.-Y.H.); (S.-Y.C.); (T.-Y.L.); (J.-S.S.); (G.-T.C.); (S.-W.F.); (T.-Y.P.)
| |
Collapse
|
4
|
Panagiotou G, Ghaly W, Upadhyay J, Pazaitou-Panayiotou K, Mantzoros CS. Serum Follistatin Is Increased in Thyroid Cancer and Is Associated With Adverse Tumor Characteristics in Humans. J Clin Endocrinol Metab 2021; 106:e2137-e2150. [PMID: 33493282 DOI: 10.1210/clinem/dgab041] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Indexed: 01/23/2023]
Abstract
CONTEXT Obesity and classical growth factors are associated with thyroid cancer (TC). However, less is known regarding novel hormones such as follistatins and activins. We hypothesized that serum follistatin but not activins would be increased in TC. OBJECTIVE This work aimed to assess circulating levels of follistatins, activins, and growth factors in patients with a history of TC vs patients with nonmalignant thyroid diseases. METHODS A hospital-based, unmatched case-control study was conducted with 170 thyroidectomized patients due to well-differentiated TC and 106 thyroidectomized patients without history of malignancy. Anthropometric, biochemical, and histological parameters were recorded. Serum samples were collected in the steady state 45 days after surgery. Multivariate models were used to adjust for baseline differences of the unmatched variables. Serum levels of follistatin (FST), follistatin like-3, activin A, activin B, bioactive insulin-like growth factor-1, and stanniocalcin-2 were assayed with novel, highly specific ELISA kits. RESULTS In unmatched univariate models, TC patients had higher FST serum levels compared to cancer-free individuals, independently of histological subtype. In multivariate models adjusting for covariates, individuals in the highest tertile of FST levels were associated with an increased risk for the presence of any type of TC or specific histological subtypes, including papillary, follicular and Hürthle-cell carcinoma, and medullary TC. Higher postoperative FST concentrations were found in patients with vascular invasion and distant metastases and associated with TNM staging at diagnosis. CONCLUSION FST serum levels are increased in TC patients and correlate with advanced tumor aggressiveness. Future longitudinal studies are needed to confirm and extend our observations.
Collapse
Affiliation(s)
- Grigorios Panagiotou
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
| | - Wael Ghaly
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
| | - Jagriti Upadhyay
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
| | | | - Christos S Mantzoros
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
| |
Collapse
|